PLAIR, the Swiss scale-up advancing pharmaceutical environmental monitoring, is proud to announce a strategic investment from bioMérieux, a global leader in the field of in vitro diagnostics.

Geneva, 16.03.2026 – PLAIR, the Swiss scale-up advancing pharmaceutical environmental monitoring, is proud to announce a strategic investment from bioMérieux, a global leader in the field of in vitro diagnostics. Headquartered in Geneva, PLAIR sees this partnership as a major endorsement of its flagship innovation, RAPID-C+, and a decisive step toward setting a new global standard for cleanroom monitoring.

This investment underscores the market’s readiness for real-time viable Biofluorescent Particle Counter (BFPC) technology. With bioMérieux becoming a strategic investor, PLAIR reinforces its mission to provide quality managers and microbiologists with clear, scientifically backed solutions for real-time viable particle counting.

PLAIR will continue working closely with its global ecosystem of partners and distributors to bring RAPID-C+ to pharmaceutical manufacturers worldwide.

“An investment from a global leader like bioMérieux brings unique synergies to PLAIR, creating significant value for all our stakeholders, partners, and RAPID-C+ users,” said Denis Kiselev, CEO of PLAIR. “The acceleration of the BFPC market demands that quality managers receive clear regulatory support and scientific guidance to adopt this new method. We strongly believe that endorsement by bioMérieux will become a strong signal for the industry, ultimately resulting in better, safer medicines for patients.”

Commenting on the partnership, Michael Reynier stated: “Our investment in PLAIR is a strategic step forward in our ambition to be the partner of choice for advancing pharmaceutical quality control. RAPID-C+ is a breakthrough innovation that will support our customers in delivering critical therapies quickly and safely to patients.”

PLAIR’s RAPID-C+ continues to stand out as a unique solution combining real-time counting of viable and total particles with certified continuous sampling on standard agar media. This dual capability enables immediate microbial identification and faster, more informed decision-making in critical cleanroom environments.